drugset
drugset / Trial / NCT02271113

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

NCT02271113 ↗

Phase 1 Completed 32 enrolled GlycoMimetics Incorporated University of Michigan · collab
RandomizedParallel-groupTriple-blindOther

Summary

In this study, the investigators will evaluate the safety, pharmacokinetics and effect on target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist, in healthy volunteers.

Timeline

Start
2014-10
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified — Subcutaneous
Subject Uproleselan Small molecule — Intravenous

Indications

No indication recorded.